|
|
|
|
|
I Spy CPhI
|
|
|
| By
Rich Whitworth
|
|
|
|
Summer can often feel like a quiet month for the pharma industry in Europe.
|
|
|
|
|
|
|
|
|
Improving R&D with API microdosing
|
|
|
| By
David Edwards
|
|
|
|
Direct dosing APIs during R&D studies can reduce the overall testing time of a drug candidate by allowing for a greater throughput of compounds through the R&D department.
|
|
|
|
The Fine Chemicals Market
|
|
|
| By
Andreas Stolle
|
|
|
|
The increased trend of outsourcing coupled with a relatively strong economy has seen the fine chemicals market grow at a very high level when compared to historical data.
|
|
|
|
Highly Potent; Highly Challenging?
|
|
|
| By
Mark Griffiths
|
|
|
|
Highly potent APIs (HPAPIs) represent a growing area of interest for the pharma industry. Mark Griffiths, CEO of Carbogen Amcis AG, explains why.
|
|
|
|
API Purification
|
|
|
| By
Peter Koklitis
|
|
|
|
Recently, there have been many innovations in the latest techniques and technologies in API purification. In particular, the trend to single-use systems has had a significant impact on processes.
|
|
|
|
HPAPIs And Bioconjugates
|
|
|
| By
Tom Gelineau
|
|
|
|
The market for HPAPIs is growing rapidly with the research industry's emphasis on oncology.
|
|
|
|
API Market Challenges
|
|
|
| By
Boris Jenniches
|
|
|
|
The increasing cost of crucial manufacturing input factors, such as energy and raw materials, has been a severe threat to several companies.
|
|
|
|
Chewing Over API Challenges
|
|
|
| By
Marc Ribe
|
|
|
|
We're all familiar with traditional pills and medicines, but how about medicated chewing gum? Marc Ribe of Cafosa Gum explains how APIs can be incorporated into a novel dosage form that can aid patient compliance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health Technology Assessment Under Scrutiny
|
|
|
| By
Nathan Jessop
|
|
|
|
The rising cost of healthcare has complicated the introduction of new, innovative drugs and other medical technologies. While the medical impact of these healthcare advances cannot be denied, governments and healthcare policy makers have found it difficult to sustain the funding of these expensive treatments.
|
|
|
|
|
|
|
|
|
News
|
|
|
| By
Stephanie Sutton
|
|
|
|
Friends in regulation
|
|
|
|
